Cover Image
市場調查報告書

個體化癌症治療藥物市場動向

Personalizing Cancer Drugs Trends

出版商 Global Industry Analysts, Inc. 商品編碼 297792
出版日期 內容資訊 英文 28 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
個體化癌症治療藥物市場動向 Personalizing Cancer Drugs Trends
出版日期: 2014年01月01日 內容資訊: 英文 28 Pages
簡介

本報告針對世界個體化癌症治療藥物市場動向進行調查分析,提供癌症瞭解、病理學意見到分子學意見見方變化概要整合、癌症遺傳學知識深度與以癌細胞為目標的多種藥劑開發促進現狀考察,目錄介紹如下。

第1章 個體化癌症治療藥物報告

第2章 市場動向與課題

  • 個別化醫療成長動向促進了癌症診斷市場
  • 進展至臨床階段的個別化醫療癌治療藥
  • 個別化治療的需求來自超過了原發性癌症範圍
  • 地區差異癌症原因:癌症治療開發主要障礙
  • 癌症個別化醫療課題
  • 個別化醫療適用保險
  • 個別化醫療的醫療提供者成功加入重點
  • 移除規範障礙是必要的
  • 提高一般人的關心
  • 科學抑制因素
  • 最近的研究進步
  • ALK基因阻礙劑進入了小兒科個別化醫療

第3章 生物標記

  • 癌症生物標記
  • 早期發現生物標記
  • 診斷生物標記
  • 預後生物標記
  • 預測生物標記
  • 藥力學生物標記
  • 生物標記:一般癌症診斷與預測
  • 乳癌
  • 淋巴腫
  • 大腸癌
  • 白血病
  • 黑色素瘤
  • 肺癌

第4章 個別化治療藥物概要

第5章 主要市場參加者

  • Cell Therapeutics, Inc.(美國)
  • F. Hoffmann-La Roche Ltd.(瑞士)
  • H3 Biomedicine, Inc.(美國)

第6章 規範機關批准

第7章 產品發售

第8章 企業嘗試

第9章 附錄

目錄
Product Code: 141065

The report illustrates that understanding of cancer is shifting from a pathology-oriented perspective to a molecular perception. Mechanisms responsible for driving cancer continue to emerge in diverse environments. In addition, the report presents an overview on the mechanism instrumental for causing some forms of breast cancer may also be responsible for promoting a subset of melanoma or brain cancer. The improved knowledge of cancer genetics is facilitating development of numerous drugs that target specific cancer cells. Cancer is one of the major chronic diseases worldwide and also the chief cause behind a huge number of fatalities. Each year, statistics post a larger figure than the previous year, indicating the rapidly growing incidence and prevalence of cancer. However, a similar pace of growth is not being reported in the area of development of drugs and therapies for treating cancers.

The report also predicts that the future holds immense promise for molecular analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with cancer treatment. Continued advances in technology are expected to lead to application of molecular analysis at each and every step in the course of cancer, ultimately enabling designing of optimal therapies, with the potential of achieving the best possible outcome, for individual patients.

Table of Contents

1. PERSONALIZING CANCER DRUGS - A FOCUS REPORT

  • Personalized Medicine in Cancer Treatment - An Overview
  • Molecular Diagnosis and Personalized Medicine Fast Gaining Ground
  • Advances in Personalized Medicine in Cancer
  • Research for Developing Tools for Genetic Profile of Tumors
  • Role of Pharmacogenomics in Personalized Therapies for Cancer
  • Modern Personalized Medicine for Cancer - A Notch above Traditional Variant
  • Genomic, Proteomic, Epigenomic and Metabolomic Information to Aid Personalized Medicine in Cancer
  • Genomic Information for Improving Efficacy of Personalized Medicine in Cancer
  • Importance of Proteomic Information in Personalized Medicine for Cancer
  • Study of Human Epigenome Contributing to Personalized Medicine for Cancer
  • Metabolomics - The Latest Addition to Personalized Medicine Domain
  • Personalized Medicine in Diagnosis and Treatment of Breast Cancer

2. MARKET TRENDS AND ISSUES

  • Growing Trend towards Personalized Medicine to Fuel the Market for Cancer Diagnostics
  • Progressing Personalized Medicine Cancer Drugs to Clinical Stage
  • Need for Personalized Therapy to Go Beyond Primary Cancers
  • Regional Differences in Cancer Causative Factors - A Major Hindrance in Development of Cancer Therapies
  • Personalized Medicine in Cancer - Issues to Address
  • Insurance Coverage for Personalized Medicine
  • Participation of Healthcare Providers Key for Success of Personalized Medicine
  • Elimination of Regulatory Hindrances a Must
  • Increasing Awareness among Public for Maximizing Benefit
  • Scientific Barriers to Address
  • Recent Progress in Research
  • ALK Gene Inhibitors Foray into Pediatric Personalized Medicine

3. BIOMARKERS

  • Biomarkers for Cancer
  • Early Detection Biomarkers
  • Diagnostic Biomarkers
  • Prognostic Biomarkers
  • Predictive Biomarkers
  • Pharmacodynamic Biomarkers
  • Biomarkers - Diagnosis and Prediction of Common Cancers
  • Breast Cancer
  • Lymphoma
  • Colon Cancer
  • Leukemia
  • Melanoma
  • Lung Cancer

4. PERSONALIZED MEDICINE - AN OVERVIEW

  • An Introduction to Personalized Medicine
  • Uniqueness of DNA and Lifestyles Necessitate Personalized Medicine
  • Understanding Genetic Variations for Developing Better Drugs and Therapies
  • Molecular Analysis for Identification of Disease Sub-Groups in Polygenic Disorders
  • Key Benefits of Molecular Analysis of Diseases
  • Early Interventions and Enhanced Diagnoses
  • Improved Drug Development Efficiency
  • More Efficient Therapies
  • Personalized Medicine - Implications Involved
  • A Perfect Intellectual Property Rights System
  • Suitable Reimbursement Policies
  • Regulatory Reviews
  • Addressing Issues of Confidentiality, Privacy and Rights of Patients
  • Future Potential of Personalized Medicine

5. NOTEWORTHY MARKET PARTICIPANTS

  • Cell Therapeutics, Inc. (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • H3 Biomedicine, Inc. (USA)

6. REGULATORY APPROVALS

  • Roche Announces FDA Approval for Perjeta™
  • Roche Receives EU Consent for Zelboraf Cancer Drug
  • Roche Receives FDA Approval for Zelboraf Cancer Drug
  • Roche Obtains EU Approval for Tarceva

7. PRODUCT LAUNCHES

  • Pfizer Canada Launches XALKORI®
  • bioTheranostics Introduces New Line of "PRECIS" Biomarkers Series

8. CORPORATE INITIATIVES

  • AlacrisTheranostics Inks Pact with GlaxoSmithKline
  • 4SC Discovery Obtains Grant for Developing New Personalized Cancer Drugs
  • Merrimack Enters into a Partnership with CTCA
  • Genomic Health Forms Strategic Alliance with OncoMed
  • Epizyme Enters into Partnership with Celgene for Advancing MLL Therapy
  • Abbott Expands Personalized Medicine Alliance with GSK
  • QIAGEN Inks Pact with Pfizer for Developing Companion Diagnostic
  • Blueprint Plans to Create Genomics-based Cancer Drugs
  • H3 Biomedicine Commences R&D Operations for Innovative Cancer Treatments
  • H3 Biomedicine Receives Research Funding from Eisai

9. APPENDIX

Back to Top